What To Do Use creative wording to promote your semaglutide weight loss program, such as Slim Shot or Skinny Shot Promote product benefits such as reduced appetite, increased metabolism, improved confidence, etc Promote the benefits of choosing your clinic and what they can expect during their time with you Use images of happy after patients and a testimonial from them Use images of diverse body types, ethnicities, and genders to attract your target audience Include information about pricing starting point, new patient discounts, financing options, or other incentives available Include any necessary disclaimers such as best used in combination with a healthy diet and exercise Use videos to explain the treatment, how it works, and include a testimonial (if available) What To Avoid Do not use the word semaglutide ever not even on your landing page or funnel Do not use phrases that are directed at the reader or that refer to their body or may be consider discriminating such as do you want to lose weight? or are you feeling fat? or struggling with obesity? Do not use imagery with a tape measure around the body as these may get flagged by Facebook Do not use before/after photos these are restricted by Facebook Do not use images with needles in them these are restricted by Facebook Do not promote how much weight the reader can lose this is a possible rejection reason (unrealistic results according to Facebook Ad guidelines) Do not use hyperbolic language that exaggerates the effects of the treatment Sample Semaglutide Ads Need Help With Your Semaglutide Facebook Ads

Restarting Ozempic After Surgery: When & How to Resume Restarting Ozempic after surgery requires careful timing and medical supervision to ensure safe recovery
If your companys plan uses a pharmacy benefit manager (PBM) with more flexible criteria, prediabetes plus obesity or other metabolic risk factors might qualify
After propensity matching, 50,590 and 47,716 patients were included in the GLP-1RAmetformin and GLP-1RAinsulin analyses, respectively
doi: 10.3389/fcell.2021.683609 Received 21 March 2021 Accepted 30 April 2021 Published 09 June 2021 Volume 9 - 2021 Edited by Jiri Novotny, Charles University, Czechia Reviewed by Flavio Maina, Aix-Marseille Universit, France